Optymyze and Kowa Pharmaceuticals Win 2015 Ventana Research Business Technology Leadership Award

Optymyze Helps Pharmaceutical Company Align and Incentivize Sales Operations, Recognized for Excellence in Sales Leadership

CHESTER, Pa. – Dec. 3, 2015 – Optymyze, a worldwide provider of enterprise cloud applications and services for improving sales and channel performance, announced today that its client Kowa Pharmaceuticals has been selected by Ventana Research as a 2015 Business Technology Leadership Award winner for Sales Excellence, based on its implementation of the Optymyze Sales Operations as a Service solution, including the company’s Sales Compensation Management platform. The award recognizes Kowa’s vice president of Sales, Brad Hardy, for leading this initiative, while highlighting how Optymyze contributes to a successful incentive compensation management (ICM) strategy.

ventana-research-award-2015 “The ability to align sales operations and compensation plans around business priorities is key to engaging sales teams, improving communications, driving increased performance and achieving better outcomes,” said Mark Stiffler, CEO of Optymyze. “Optymyze is committed to helping companies like Kowa implement the technology and services to do just that. We are thrilled that Brad and his team have been recognized by Ventana for achieving sales excellence and proud to have helped them transform their incentive compensation strategy with a combination of technology and processes, working hand in glove, to build and maintain a more engaged sales force.”

Kowa Pharmaceuticals is a specialty pharmaceutical company focused primarily in the area of cardiometabolic therapeutics. As the company continues to grow its presence and evolve, it found that its existing ICM solution and processes were not agile enough to keep up with its changing needs. Recognizing the opportunity to improve this crucial operation, the company sought a solution that could deliver better outcomes, increase sales efficiency and incent behaviors in alignment with company goals.

After considering a number of vendors, Kowa found that Optymyze was uniquely qualified to help improve incentive compensation management, provide greater visibility into the process, enhance compensation data accuracy and connect incentive spend to financial results. Kowa outsourced the majority of its sales operations function to Optymyze, leveraging dedicated access to consultants who are responsible for all compensation related activities, including plan recommendations, design and modeling; quota methodology design, change management initiatives; reporting, new hire training and more. Optymyze’s Sales Compensation Management technology was a key component of the solution, helping the pharmaceutical company create a more agile salesforce.

Following Kowa’s implementation, the company has aligned incentive compensation plans with corporate goals and tied incentive payments to revenue. Improved compensation accuracy has resulted in greater confidence among the sales force in their compensation as well as improved engagement. As a result, quota attainment has increased significantly, and with improved communications, the company benefits from greater consistency across its sales operations, leading to the prestigious distinction as a 2015 Business Technology Leadership Award winner.

“Congrats to Brad Hardy and the Kowa Pharmaceuticals team for its 2015 Ventana Research Leadership Award in Sales Excellence,” said Mark Smith, CEO and chief research officer. “Through the use of Optymyze, a more efficient sales compensation process and focus on improving outcomes was leveraged, helping Kowa be more successful in its sales efforts.”

Ventana Research’s 2015 Business Technology leadership Awards recognize organizations and individuals who have achieved notable success in leading change, increasing productivity and attaining superior business outcomes. Award recipients are selected based on leadership, business and technology criteria in 27 specific categories and on the extent to which organizations have transformed business or IT processes. Additional information can be accessed at: http://www.ventanaresearch.com/Leadershipawards/

About Kowa Company, Ltd. and Kowa Pharmaceuticals America, Inc.
Kowa Company, Ltd. (Kowa) is a privately held multinational company headquartered in Nagoya, Japan. Established in 1894, Kowa is actively engaged in various manufacturing and trading activities in the fields of pharmaceuticals, life science, information technology, textiles, machinery and various consumer products. Kowa’s pharmaceutical division is focused on research and development for cardiovascular therapeutics (dyslipidemia, type 2 diabetes and atherosclerosis), ophthalmology and anti-inflammatory agents. The company’s flagship product, LIVALO® (pitavastatin), is approved in 45 countries around the world.

Kowa Pharmaceuticals America, Inc., headquartered in Montgomery, AL, is focused primarily in the area of cardiometabolic diseases. Established in September 2008, Kowa Pharmaceuticals America focuses its efforts on the successful commercialization of its current and near-term portfolio of pharmaceutical products, and business development activities. For more information about Kowa Pharmaceuticals America, visit www.kowapharma.com.

About Optymyze
Optymyze helps companies improve sales force and sales operations performance with enterprise cloud applications and business process management services for aligning sales goals and compensation; efficiently executing sales strategies; driving faster increases in sales results; and gaining visibility into sales performance. With Optymyze Sales Operations as a Service, customers are able to turn sales operations into a strategic business advantage through agility, innovation, and continuous improvement. Optymyze was named the top-most Visionary in the 2015 Gartner Magic Quadrant for Sales Performance Management. Learn more about Optymyze: Web | Twitter | LinkedIn

Media Contact:
Jeanne Achille
The Devon Group
New York Metro Office: +1 (732) 706-0123, ext. 100

Privacy >